DNTH
Dianthus Therapeutics Inc

1,241
Mkt Cap
$1.75B
Volume
1.57M
52W High
$41.15
52W Low
$13.37
PE Ratio
-11.70
DNTH Fundamentals
Price
$40.85
Prev Close
$35.50
Open
$34.56
50D MA
$35.94
Beta
0.95
Avg. Volume
548,890.09
EPS (Annual)
-$2.55
P/B
3.20
Rev/Employee
$79,935.90
Loading...
Loading...
News
all
press releases
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.7% - Here's What Happened
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 6.7% - Should You Buy...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) EVP Simrat Randhawa Sells 87,507 Shares
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 87,507 shares of the business's stock in a transaction on Thursday, November 13th. The shares were sold at an...
MarketBeat·22h ago
News Placeholder
HC Wainwright Increases Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $47.00
HC Wainwright increased their price target on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a "buy" rating in a research report on Monday...
MarketBeat·5d ago
News Placeholder
Equities Analysts Offer Predictions for DNTH FY2025 Earnings
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Wedbush lowered their FY2025 earnings per share estimates for shares of Dianthus Therapeutics in a research report issued on Thursday...
MarketBeat·6d ago
News Placeholder
FY2025 EPS Estimate for Dianthus Therapeutics Cut by Analyst
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Equities researchers at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a note...
MarketBeat·6d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Wedbush Analyst Says
Wedbush raised their price objective on Dianthus Therapeutics from $44.00 to $46.00 and gave the company an "outperform" rating in a report on Thursday...
MarketBeat·9d ago
News Placeholder
Dianthus Therapeutics (NASDAQ:DNTH) Posts Earnings Results, Misses Estimates By $0.11 EPS
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the...
MarketBeat·9d ago
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -12.79% and -39.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of +32.14% and +5.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?
Dianthus Therapeutics, Inc. (DNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·17d ago

Latest DNTH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.